Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) (Genvoya) fixed-dose combination, oral tablet
The objective of this systematic review is to evaluate of the beneficial and harmful effects of the fixed-dose combination (FDC) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 2016 Nov
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this systematic review is to evaluate of the beneficial and harmful effects of the fixed-dose combination (FDC) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients 12 years of age and older with no known mutations associated with resistance to the individual components of EVG/COBI/FTC/TAF. |
|---|---|
| Physical Description: | 1 online resource illustration |